

HeLa 229 Cells | 305056

General information

Description

The HeLa 229 cell line is a clonal derivative of the original HeLa cell line, which was the first human cell line to be continuously cultured. HeLa cells were derived from cervical cancer cells taken from Henrietta Lacks in 1951. The HeLa 229 subline is utilized in various areas of biomedical research, including cancer research, drug development, and toxicology, due to its robust growth and adaptability under laboratory conditions.

One of the main characteristics of the HeLa 229 cell line is its aggressive growth and proliferation, reflecting the cancerous origin of the cells. This makes it particularly useful for studies requiring high cell yields and rapid growth, such as high-throughput screening for drug discovery. HeLa 229 cells are also highly amenable to genetic manipulation, allowing researchers to introduce foreign genes or specific mutations to study their effects on cell behavior and pathology.

HeLa 229 cells continue to be a critical model in virology, as they are susceptible to a wide variety of viruses. This susceptibility makes them an excellent tool for studying viral life cycles, host-virus interactions, and the efficacy of antiviral compounds. The cell line has also been instrumental in advancing our understanding of fundamental cellular processes, such as DNA replication, transcription, and apoptosis.

Despite their utility, the use of HeLa cells, including HeLa 229, raises ethical considerations regarding consent and the origins of the cell line, as the cells were originally obtained without the consent of Henrietta Lacks or her family. However, ongoing research with HeLa cells continues to contribute significantly to science, driven by their unique characteristics and historical importance in the development of modern cell biology.

Organism

Human

Tissue

Cervix

Disease

Human papillomavirus-related endocervical adenocarcinoma

Synonyms

HeLa-229, HeLa229

Characteristics

Age

31 years

Gender

Female

Morphology

Epithelial

Growth properties

Adherent

Regulatory Data

Hela 229 Cells | 305056**Citation** Hela 229 (Cytion catalog number 305056)**Biosafety level** 1**NCBI_TaxID** 9606**CellosaurusAccession** CVCL_1276**Biomolecular Data****Handling****Culture Medium** EMEM (MEM Eagle), w: 2 mM L-Glutamine, w: 2.2 g/L NaHCO₃, w: EBSS (Cytion article number 820100a)**Doubling time** 26 hours**Subculturing** Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.**Split ratio** 1:2 to 1:5**Fluid renewal** 2 to 3 times per week**Freeze medium** As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.**Quality Control & Molecular Analysis****Sterility**

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

Hela 229 Cells | 305056

STR profile

Amelogenin: x,x
CSF1PO: 9,1
D13S317: 12,13.3
D16S539: 9,1
D5S818: 11,12
D7S820: 8,12
TH01: 7
TPOX: 8,12
vWA: 16,18
D3S1358: 15,18
D21S11: 27,28
D18S51: 16
Penta E: 7,17
Penta D: 8,15
D8S1179: 12,13
FGA: 18,21
D6S1043: 18
D2S1338: 17
D12S391: 20,25
D19S433: 13,14